Fed. Circ. Nixes Abraxis Win In Naropin Patent Row
A divided three-judge panel for the U.S. Court of Appeals for the Federal Circuit ruled Tuesday that a district court should have granted Navinta's motion to dismiss because Abraxis did not technically hold title over the patents when it filed suit in March 2007.
Abraxis had agreed to buy the patents covering Naropin from AstraZeneca PLC in 2006, but...
Already a subscriber? Click here to login